KH
KHRNF.US Khiron Life Sciences Corp
- Market cap
- USD 2.32K
- P/E
- -
- P/B
- 0.00x
- ROE
- -54.9%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2022.
Is KHRNF.US undervalued?
Graham numberThe Graham number of Khiron Life Sciences Corp cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Khiron Life Sciences Corp fundamental analysis
No fundamental analysis for Khiron Life Sciences Corp yet.
Khiron Life Sciences Corp stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Khiron Life Sciences Corp
Khiron Life Sciences Corp. operates as a medical cannabis company in Latin America and Europe. It engages in the cultivation, production, distribution, and export of tetrahydrocannabinol medical cannabis products. The company is also involved in the operation of health centers under the Zerenia and Dr. Zerenia brand names; and provision of medical education and training programs for health professionals. It sells its products in Colombia, Peru, Germany, the United Kingdom, B…
Full company profileKhiron Life Sciences Corp financial statements
2022 annualized: Fiscal year 2022 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2022, the balance sheet is the latest quarter. Figures change when the annual report is published.
Khiron Life Sciences Corp annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | - | - | - | 0.00 | 0.00 | 0.00 | 892K | 9.58M | 8.02M | 12.8M | 16.7M |
| Gross Profit | - | - | - | 0.00 | 0.00 | 0.00 | 297K | 2.44M | 7.01M | 6.37M | 7.33M |
| Operating Income | -208K | -126K | -116K | -59.6K | -44.7K | -4.52M | -19.9M | -37.4M | -23.6M | -19.8M | -15.3M |
| EBITDA | -208K | -126K | -116K | -59.6K | - | -4.52M | -18.3M | -36.5M | -22.3M | -32.0M | -13.4M |
| Net Income | -208K | -126K | -116K | -59.6K | -44.7K | -4.54M | -19.8M | -36.4M | -24.0M | -33.1M | -14.9M |
| EPS | -1.48 | -0.49 | -0.50 | -0.31 | -0.24 | -0.16 | -0.41 | -0.36 | -0.20 | -0.20 | -0.07 |
| Balance Sheet | |||||||||||
| Total Assets | 212K | 118K | 35.1K | 6.76K | 9.46K | 148K | 40.3M | 81.9M | 73.2M | 42.3M | 38.5M |
| Total Liabilities | 33.4K | 90.4K | 30.1K | 104K | 117K | 12.6K | 14.8M | 11.9M | 9.95M | 8.95M | 11.3M |
| Shareholders' Equity | 179K | 27.7K | 4.97K | -96.9K | -108K | 135K | 25.5M | 70.0M | 63.2M | 33.3M | 27.1M |
| Cash & Short-term Investments | 205K | 86.3K | 3.36K | 13.00 | 4.96K | 148K | 19.0M | 36.9M | 21.6M | 8.92M | 1.94M |
| Total Debt | - | - | - | 0.00 | 0.00 | - | 2.51M | 3.55M | 2.79M | 2.23M | 2.56M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -128K | -140K | -96.4K | -58.2K | -21.3K | -21.3K | -14.8M | -30.1M | -24.5M | -20.4M | -13.1M |
| Capital Expenditure | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 292K | 3.83M | 6.09M | 2.69M | 1.74M | 2.21M |
| Free Cash Flow | -128K | -140K | -96.4K | -58.2K | -21.3K | -21.3K | -18.6M | -36.2M | -27.2M | -22.1M | -15.3M |
| Ratios | |||||||||||
| ROE | -116.4% | -453.4% | -2,329.9% | - | - | -3,362.1% | -77.6% | -51.9% | -38.0% | -99.4% | -54.9% |
| ROA | -98.0% | -106.3% | -329.8% | -880.6% | -472.3% | -3,074.4% | -49.1% | -44.4% | -32.8% | -78.4% | -38.7% |
| Net Profit Margin | - | - | - | - | - | - | -2,221.3% | -379.6% | -299.8% | -258.9% | -89.3% |
| Debt to Equity | - | - | - | - | - | - | 0.10x | 0.05x | 0.04x | 0.07x | 0.09x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Khiron Life Sciences Corp dividends
Khiron Life Sciences Corp has not paid dividends in the last 9 fiscal years.
Who owns Khiron Life Sciences Corp
- Insiders 0.00%
- Institutions 0.22%
- Public & others 99.79%
- Shares outstanding 232M
- Free float 205M
Khiron Life Sciences Corp company profile
- Company name
- Khiron Life Sciences Corp
- Ticker
- KHRNF.US
- ISIN
- CA49374L3065
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Fiscal year end
- December
- Address
- Carrera 11 #84-09, Bogota, Colombia
- Phone
- 57 1 744 2064
- Website
- khiron.ca
About Khiron Life Sciences Corp
Khiron Life Sciences Corp. operates as a medical cannabis company in Latin America and Europe. It engages in the cultivation, production, distribution, and export of tetrahydrocannabinol medical cannabis products. The company is also involved in the operation of health centers under the Zerenia and Dr. Zerenia brand names; and provision of medical education and training programs for health professionals. It sells its products in Colombia, Peru, Germany, the United Kingdom, Brazil, Uruguay, and Mexico. The company is headquartered in Bogota, Colombia.
Khiron Life Sciences Corp management
5- Dr. Alvaro Francisco TorresCo-Founder, CEO & Director · born 1979
- Ms. Franziska KatterbachPresident of Khiron Europe
- Mr. Swapan Kakumanu ACA, ACWA, CGACorporate Secretary · born 1970
- Mr. Michael John O'Connor MAChief Financial Officer · born 1967
- Mr. Marco AlgortaCountry Manager of Uruguay